Research programme: anti-ischaemic therapeutics - Quantum GenomicsAlternative Names: QGC 002
Latest Information Update: 16 Jul 2016
At a glance
- Originator INSERM
- Class Recombinant proteins
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Ischaemia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Ischaemia in France (Parenteral)
- 25 Jan 2008 Preclinical trials in Ischaemia in France (Parenteral)